KD-4002 is under clinical development by Kyung Dong and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KD-4002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KD-4002 is under development for the treatment of type 2 diabetes. It is an incrementally modified drug (IMD). It is administered through oral route.
Kyung Dong overview
Kyung Dong is engaged in coal mining. It offers mining and general, power plants, public projects, domestic resource development and overseas resource development services. Kyung Dong is headquartered in Siheung-si, Gyeonggi-do, South Korea.
For a complete picture of KD-4002’s drug-specific PTSR and LoA scores, buy the report here.